Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Organon, Roivant
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click here to read my most recent analysis.
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.
Organon to buy Roivant's dermatology unit for up to $1.2 billion
Shares of
Roivant
, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading. However,
Organon
was down 1.4%. Dermavant's Vtama cream, approved by ...
Roivant makes another deal, selling Dermavant to Organon for up to $1.2B
Roivant is once again reaping the benefits of its bespoke business model. This time, it's selling Dermavant to Organon for up to $1.2 billion. Most of that money — $950 million — is available via commercial milestones,
Organon to acquire Dermavant in $1.2B deal
The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion
Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million, along with up to $1.025 billion in milestone payments.
5d
on MSN
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...
FiercePharma
5d
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
Organon
is set to acquire
Roivant
’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies ...
1d
Organon: A Surprising Deal
Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...
4d
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...
pharmaphorum
4d
Organon makes dermatology play with $1.2bn Dermavant buyout
Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...
5d
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback